Published in Br J Pharmacol on May 01, 2014
The pharmacology of TRP channels. Br J Pharmacol (2014) 0.87
The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 30.59
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 10.05
Cellular and molecular mechanisms of pain. Cell (2009) 9.36
TRP channels. Annu Rev Biochem (2007) 8.09
Molecular basis for species-specific sensitivity to "hot" chili peppers. Cell (2002) 4.57
Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A (2000) 4.53
Virtual computational chemistry laboratory--design and description. J Comput Aided Mol Des (2005) 3.83
Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov (2009) 2.88
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature (2006) 2.47
Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel. J Neurosci (1999) 2.29
Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov (2011) 2.25
Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem (2004) 2.17
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem (2001) 2.13
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett (2000) 2.11
Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience (2006) 2.07
Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol (2009) 2.00
A bivalent tarantula toxin activates the capsaicin receptor, TRPV1, by targeting the outer pore domain. Cell (2010) 1.82
A yeast genetic screen reveals a critical role for the pore helix domain in TRP channel gating. Neuron (2008) 1.79
Recent developments in vascular endothelial cell transient receptor potential channels. Circ Res (2005) 1.73
Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol Pharmacol (2001) 1.73
Transient receptor potential channelopathies. Pflugers Arch (2010) 1.40
Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem (2005) 1.39
Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun (1999) 1.35
TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in mice. Circulation (2005) 1.32
Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells. Mol Cancer Ther (2006) 1.26
TRPV1: on the road to pain relief. Curr Mol Pharmacol (2008) 1.26
Advances in modulating thermosensory TRP channels. Expert Opin Ther Pat (2012) 1.21
The distribution and regulation of vanilloid receptor VR1 and VR1 5' splice variant RNA expression in rat. Neuroscience (2001) 1.16
Reactive oxygen species and nitric oxide regulate mitochondria-dependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells. Free Radic Res (2008) 1.16
Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. Eur J Pharmacol (2006) 1.15
Agonist recognition sites in the cytosolic tails of vanilloid receptor 1. J Biol Chem (2002) 1.14
Alkaloids isolated from natural herbs as the anticancer agents. Evid Based Complement Alternat Med (2012) 1.13
Identification of species-specific determinants of the action of the antagonist capsazepine and the agonist PPAHV on TRPV1. J Biol Chem (2004) 1.13
Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut (2005) 1.09
Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules (2009) 1.08
Analgesic potential of TRPV1 antagonists. Biochem Pharmacol (2009) 1.08
Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med (2001) 1.05
Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling. Endocrinology (2007) 1.05
Molecular mechanisms of activation of endothelial nitric oxide synthase mediated by transient receptor potential vanilloid type 1. Cardiovasc Res (2011) 1.04
Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential. J Pharmacol Exp Ther (2004) 1.01
The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med (2003) 1.01
Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sci (2005) 0.99
Structural insights into transient receptor potential vanilloid type 1 (TRPV1) from homology modeling, flexible docking, and mutational studies. J Comput Aided Mol Des (2011) 0.99
Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J Cell Biochem (2007) 0.96
Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205). Chem Biodivers (2009) 0.95
Agonist- and Ca2+-dependent desensitization of TRPV1 channel targets the receptor to lysosomes for degradation. J Biol Chem (2012) 0.93
Structure-activity relationships of vanilloid receptor agonists for arteriolar TRPV1. Br J Pharmacol (2012) 0.92
20-Hydroxyeicosatetraenoic acid (20-HETE) is a novel activator of transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem (2012) 0.92
Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis (2005) 0.92
Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity. Eur J Pharmacol (2010) 0.90
Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells. Anticancer Drugs (2010) 0.90
Kinetics of penetration influence the apparent potency of vanilloids on TRPV1. Mol Pharmacol (2006) 0.89
Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer (2004) 0.89
Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis. Acta Physiol (Oxf) (2012) 0.89
New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. J Med Chem (2012) 0.88
Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells. Cancer Lett (2012) 0.88
Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J Cell Biochem (2010) 0.88
Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org Biomol Chem (2004) 0.87
A re-evaluation of 9-HODE activity at TRPV1 channels in comparison with anandamide: enantioselectivity and effects at other TRP channels and in sensory neurons. Br J Pharmacol (2012) 0.87
Effect of the TRPV1 antagonist SB-705498 on the nasal parasympathetic reflex response in the ovalbumin sensitized guinea pig. Br J Pharmacol (2013) 0.86
Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicol In Vitro (2009) 0.86
Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetes. Int J Obes (Lond) (2009) 0.85
TRPV1 and SP: key elements for sepsis outcome? Br J Pharmacol (2013) 0.85
Inhibition of airway hyper-responsiveness by TRPV1 antagonists (SB-705498 and PF-04065463) in the unanaesthetized, ovalbumin-sensitized guinea pig. Br J Pharmacol (2012) 0.85
Protective effects of evodiamine on myocardial ischemia-reperfusion injury in rats. Planta Med (2004) 0.84
Tricyclic 3,4-dihydropyrimidine-2-thione derivatives as potent TRPA1 antagonists. Bioorg Med Chem Lett (2011) 0.83
N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. Pharmacol Res (2011) 0.83
Evodiamine inhibits in vitro angiogenesis: Implication for antitumorgenicity. Life Sci (2005) 0.82
Binding mode pediction of evodiamine within vanilloid receptor TRPV1. Int J Mol Sci (2012) 0.82
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem (2009) 0.82
Protective effects of calcitonin gene-related peptide-mediated evodiamine on guinea-pig cardiac anaphylaxis. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.81
Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa. J Nat Prod (1996) 0.80
N-1-Alkyl-2-oxo-2-aryl amides as novel antagonists of the TRPA1 receptor. Bioorg Med Chem Lett (2012) 0.80
The bronchoconstrictive action of evodiamine, an indoloquinazoline alkaloid isolated from the fruits of Evodia rutaecarpa, on guinea-pig isolated bronchus: possible involvement on vanilloid receptors. Planta Med (2000) 0.80
Tetrahydro-β-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels. Bioorg Med Chem Lett (2012) 0.80
Arylglycine derivatives as potent transient receptor potential melastatin 8 (TRPM8) antagonists. Bioorg Med Chem Lett (2013) 0.80
First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands. FEBS Lett (2005) 0.79
Fatty acyl amides of endogenous tetrahydroisoquinolines are active at the recombinant human TRPV1 receptor. Bioorg Med Chem (2007) 0.79
Evodiamine activates autophagy as a cytoprotective response in murine Lewis lung carcinoma cells. Oncol Rep (2012) 0.78
Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model. Bioorg Med Chem Lett (2007) 0.76
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol (2003) 3.60
The molecular receptive ranges of human TAS2R bitter taste receptors. Chem Senses (2009) 3.45
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A (2002) 3.16
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab (2006) 2.72
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
From pyrroles to 1-oxo-2,3,4,9-tetrahydro-1H-beta-carbolines: a new class of orally bioavailable mGluR1 antagonists. Bioorg Med Chem Lett (2007) 2.06
Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol (2009) 2.00
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
Possible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 1.89
Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem (2004) 1.87
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Endocannabinoids and the control of energy balance. Trends Endocrinol Metab (2006) 1.74
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain (2011) 1.70
The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab (2013) 1.67
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med (Berl) (2007) 1.65
Biochemistry and pharmacology of endovanilloids. Pharmacol Ther (2007) 1.64
The transient receptor potential channel TRPA1: from gene to pathophysiology. Pflugers Arch (2012) 1.63
Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: Identification of novel proapoptotic agents. Bioorg Med Chem (2010) 1.63
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther (2006) 1.61
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology (2003) 1.60
Broad tuning of the human bitter taste receptor hTAS2R46 to various sesquiterpene lactones, clerodane and labdane diterpenoids, strychnine, and denatonium. J Agric Food Chem (2007) 1.59
Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther (2005) 1.56
Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol (2009) 1.55
Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology (2006) 1.54
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci (2004) 1.52
Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) (2008) 1.51
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J (2005) 1.48
N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem (2003) 1.48
Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A (2008) 1.47
Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 1.41
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Functional characterization of transient receptor potential channels in mouse urothelial cells. Am J Physiol Renal Physiol (2009) 1.39
Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr (2009) 1.39
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res (2002) 1.38
Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci (2006) 1.37
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J (2006) 1.36
An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab (2009) 1.36
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs (2010) 1.34
Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology (2005) 1.33
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta (2006) 1.31
Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J Physiol (2006) 1.30
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol (2003) 1.30
Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol (2008) 1.30
Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis (2003) 1.29
Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol (2003) 1.29
Hyperforin inhibits cancer invasion and metastasis. Cancer Res (2004) 1.27
Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev (2010) 1.26
An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Angew Chem Int Ed Engl (2011) 1.26
The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav (2005) 1.25
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther (2008) 1.25
Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One (2011) 1.24
Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol (2002) 1.24
Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. Eur J Pharmacol (2004) 1.24
Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem (2002) 1.22
Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology (2008) 1.21
Evolutionary origins of the endocannabinoid system. Gene (2006) 1.21
Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res (2005) 1.21
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21
TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des (2008) 1.21
Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci (2007) 1.20
Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod (2011) 1.19
N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie (2010) 1.19
Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets (2010) 1.19
Endocannabinoids link feeding state and auditory perception-related gene expression. J Neurosci (2004) 1.18
TRPV1 channels control synaptic plasticity in the developing superior colliculus. J Physiol (2009) 1.17
Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem (2008) 1.16
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A (2011) 1.16
Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J (2004) 1.16
Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J (2003) 1.15
Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med (2012) 1.15
Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Exp Cell Res (2007) 1.14
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology (2006) 1.14
Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology (2005) 1.12
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) (2007) 1.12
Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol Hum Reprod (2002) 1.12
DAG lipase involvement in depolarization-induced suppression of inhibition: does endocannabinoid biosynthesis always meet the demand? Neuroscientist (2010) 1.12
Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun (2005) 1.11
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des (2002) 1.10
The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis (2008) 1.10
Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med (2005) 1.09
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis (2010) 1.09
Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol (2009) 1.09
Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med (2002) 1.09
Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes (2011) 1.08
The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A (2009) 1.08
Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (Berl) (2007) 1.07